- MeSH
- adipokiny izolace a purifikace metabolismus MeSH
- cytokiny izolace a purifikace metabolismus MeSH
- diabetes mellitus 2. typu * epidemiologie etiologie komplikace MeSH
- gastrointestinální nádory etiologie komplikace metabolismus MeSH
- hyperglykemie komplikace krev metabolismus MeSH
- hyperinzulinismus komplikace krev metabolismus MeSH
- insulinu podobný růstový faktor I MeSH
- komplikace diabetu etiologie metabolismus MeSH
- leptin izolace a purifikace metabolismus MeSH
- lidé MeSH
- nádory endometria etiologie komplikace metabolismus MeSH
- nádory ledvin etiologie komplikace metabolismus MeSH
- nádory močového měchýře etiologie komplikace metabolismus MeSH
- nádory prsu etiologie komplikace metabolismus MeSH
- nádory * epidemiologie etiologie metabolismus MeSH
- nehodgkinský lymfom etiologie komplikace metabolismus MeSH
- obezita epidemiologie etiologie komplikace MeSH
- statistika jako téma MeSH
- tuková tkáň * enzymologie metabolismus sekrece MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
Digestive cancers are the most severe complications of celiac disease (CD), which can lead to death. We can report 12 patients with CD associated with cancer. It is retrospective study of 12 patients with CD complicated by cancers, collected in the department of diseases of the digestive system "Medicine C", from 1995 to 2017. Six patients had lymphoma, three were gastric tumors, two were small intestine tumors, and one had liver tumor. The diagnosis of lymphoma was made at the same time as that of CD in one patient, three months later in two patients, 18 months later in two patients and 8 years later in one patient. Morphological and histological data were in favor of malignant non-Hodgkin's lymphoma with intestinal localization in four patients, with lymph node localization in one patient and one patient with refractory celiac disease type 2 with intraepithelial lymphoma. The treatment consisted of chemotherapy in four patients and corticosteroid therapy with parenteral nutrition in one patient. The evolution was marked by the death of 03 patients and 2 patients were lost without any idea about their evolution. The diagnosis of the gastric tumor was retained after the realization of a upper gastrointestinal endoscopy with biopsies. The histopathologic examination was in favor of a well-differentiated adenocarcinoma in two patients, and of an adenocarcinoma moderately differentiated in one patient. The diagnosis of the well-differentiated neuroendocrine tumor was carried out 30 years after that of CD. The patient underwent a resection of the first two duodenal portions with duodeno-jejunal anastomosis and a colonic resection with termino-terminal anastomosis. The evolution was good with a 2 years follow-up. The second patient with intestinal cancer was a moderately differentiated adenocarcinoma of intestinal origin; the diagnosis was retained after an abdominal CT scan with mass biopsy. The treatment was palliative chemotherapy, with an abdominal scan three months later showed partial response. The hepatocellular carcinoma on healthy liver was diagnosed at the same time as CD on angio-CT scan data and liver biopsy with patient death at the time of diagnosis. Digestive cancers are severe complications of CD requiring early management and follow-up of patients to reduce the rate of death.
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD. RESULTS: Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population. CONCLUSION: This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.
- MeSH
- antirevmatika terapeutické užití MeSH
- B-buněčný lymfom epidemiologie etiologie MeSH
- inhibitory TNF MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom T-buněčný epidemiologie etiologie MeSH
- lymfom epidemiologie etiologie patologie MeSH
- nehodgkinský lymfom epidemiologie etiologie MeSH
- registrace MeSH
- revmatoidní artritida komplikace farmakoterapie MeSH
- rizikové faktory MeSH
- tumor nekrotizující faktory MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Klíčová slova
- brentuximab-vedotin, idelalisib, ibrutinib, temsirolimus,
- MeSH
- antitumorózní látky terapeutické užití MeSH
- bexaroten MeSH
- bortezomib MeSH
- inhibitory histondeacetylas terapeutické užití MeSH
- lenalidomid MeSH
- lidé MeSH
- nehodgkinský lymfom * etiologie farmakoterapie patofyziologie MeSH
- protokoly antitumorózní kombinované chemoterapie * MeSH
- protokoly protinádorové léčby MeSH
- rituximab terapeutické užití MeSH
- sirolimus analogy a deriváty aplikace a dávkování farmakologie škodlivé účinky terapeutické užití MeSH
- tetrahydronaftaleny aplikace a dávkování farmakologie škodlivé účinky terapeutické užití MeSH
- thalidomid analogy a deriváty aplikace a dávkování terapeutické užití MeSH
- Check Tag
- lidé MeSH
AIM: An epidemiological cross-sectional study was conducted to evaluate the association between cutaneous melanoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma in 40 European countries. METHODS: Incidence rates were obtained from the database of the International Agency for Research of Cancer (IARC). We analyzed age-adjusted and gender-stratified incidence rates for cutaneous melanoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma in 40 European countries. All European countries included had registration systems that fulfilled the quality criteria of IARC. Normal distribution of the variables was examined using Kolmorov-Smirnov test before calculating their correlations using Pearson's Correlation test. RESULTS: In males, positive correlations were found between cutaneous melanoma, Hodgkin's lymphoma (r=0.14, p=0.38), and non-Hodgkin's lymphoma (r=0.64, p<0.001). In females, negative correlation was found between cutaneous melanoma and Hodgkin's lymphoma (r=0.28, p=0.08), however, positive correlation was found between cutaneous melanoma and non-Hodgkin's lymphoma (r=0.72, p<0.001). CONCLUSION: Our findings raise the hypothesis about common risk factors for cutaneous melanoma and non-Hodgkin's lymphoma. New epidemiological and genetic studies are needed to identify possible common risk factors.
- MeSH
- Hodgkinova nemoc epidemiologie etiologie MeSH
- incidence MeSH
- lidé MeSH
- melanom epidemiologie etiologie MeSH
- nehodgkinský lymfom epidemiologie etiologie MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
- Klíčová slova
- mitogenní aktivita, inzulinová potenciační léčba, Anti-IGF-1R léčba, cílená protinádorová léčba,
- MeSH
- diabetes mellitus 1. typu diagnóza terapie MeSH
- diabetes mellitus 2. typu * diagnóza komplikace mortalita MeSH
- duktální karcinom pankreatu diagnóza chemicky indukované MeSH
- epidemiologické studie MeSH
- hepatocelulární karcinom diagnóza MeSH
- hyperinzulinismus MeSH
- insulinu podobný růstový faktor I farmakologie škodlivé účinky MeSH
- insulinu podobný růstový faktor II farmakologie škodlivé účinky MeSH
- inzulin farmakologie terapeutické užití MeSH
- karcinom * diagnóza MeSH
- kolorektální nádory diagnóza etiologie MeSH
- komorbidita MeSH
- lidé MeSH
- metaanalýza jako téma MeSH
- metformin aplikace a dávkování farmakologie terapeutické užití MeSH
- nádory endometria diagnóza MeSH
- nádory ledvin diagnóza MeSH
- nádory močového měchýře diagnóza MeSH
- nádory prsu diagnóza MeSH
- nádory * diagnóza etiologie terapie MeSH
- nehodgkinský lymfom diagnóza etiologie MeSH
- rizikové faktory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Sdělení dokumentuje případ nemocné s koincidencí pneumonie, hypogamaglobulinemie, autoimunitní hemolytické anemie a non-Hodgkinského lymfomu. V příspěvku jsou diskutovány možné příčiny, diagnostika a léčba autoimunitních hemolytických anemií.
The paper documents a case of a female patient with a coincidence of a pneumonia, hypogamaglobulinemia, autoimmune hemolytic anemia and non-Hodgkin lymphoma. Possible causes, diagnostic procedures and the treatment of autoimmune hemolytic anemia are discussed in our paper.
- Klíčová slova
- autoimunitní hemolytická anemie, non-Hodgkinský lymfor, běžný variabilní imunodeficit,
- MeSH
- agamaglobulinemie diagnóza etiologie terapie MeSH
- autoimunitní hemolytická anemie diagnóza etiologie terapie MeSH
- běžná variabilní imunodeficience diagnóza etiologie terapie MeSH
- diferenciální diagnóza MeSH
- komorbidita MeSH
- lidé MeSH
- nehodgkinský lymfom diagnóza etiologie terapie MeSH
- pneumonie diagnóza etiologie terapie MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- Klíčová slova
- B-NHL BFM 2004,
- MeSH
- dítě MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- mladiství MeSH
- nehodgkinský lymfom * diagnóza etiologie terapie MeSH
- protokoly protinádorové léčby MeSH
- staging nádorů MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- práce podpořená grantem MeSH
Non-HodgkinovT-lymfóm asociovaný s enteropatiou (EATL) je nádor buniek zodpovedajúcich intraepitelovým lymfocytom T-radu tenkého čreva s heterogenitou morfologického obrazu a klinického priebehu, a to najmä v závislosti od stupňa blastickej transformácie nádorových buniek. Vyskytuje sa najmä v súvislosti s malabsorpčným syndrómom, predovšetkým s celiakiou, ktorá sa pokladá za prekancerózu tohto nádorového ochorenia. Za rizikové faktory rozvoja tejto malígnej komplikácie u pacientov s celiakiou sa považuje doba expozície lepku, celiakia diagnostikovaná vo vyššom veku a celiakia refraktérna na liečbu. Ide o veľmi závažné ochorenie s veľmi zlou prognózou a vysokou mortalitou. Autori predkladajú klinický prípad pacientky s neskoro diagnostikovanou celiakiou vo vyššom veku, komplikovanou vznikom EATL. Cieľom našej práce je poukázať na význam celiakie ako prekancerózy u pacientov stredného a staršieho veku a na alarmujúcu situáciu v epidemiológii celiakie súvisiacu s výrazným poddiagnostikovaním tohto ochorenia v populácii.
Enteropathy-associated non-Hodgkin T-lymphoma (EATL) is a tumor of intraepithelial T-lymphocytes of the small intestine with heterogeneous morphologic and clinical picture dependent on the degree of malignant transformation of the cells. This disease is presented as a malabsorption of mostly čeliac origin which is supposed to be a precancerosis of this tumorous condition. The risk factors of the malignant complication development in patients with čeliac are the gluten exposure time, čeliac diagnosed in older patients and čeliac refractory to the treatment. It is a serious disease with poor prognosis and high mortality. The authors present the clinical case of a patient who was diagnosed with čeliac late and at a high age, complicated by the occurrence of EATL. This paper aims to point out the significance of čeliac as precancerosis in patients of intermediate and older age and the alarming situation in čeliac epidemiology related to the distinctive underdiagnosis of this disease in the population.
- MeSH
- celiakie diagnóza komplikace patologie MeSH
- lidé MeSH
- nehodgkinský lymfom diagnóza etiologie MeSH
- prekancerózy MeSH
- prognóza MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
